Smart medical testing device launched to help relieve pressure on healthcare systems

Medtech company Bloom Diagnostics launches a smart medical testing solution in Europe and applies for approval in the US.

  • Smart healthcare device allows users to carry out a range of tests in minutes
  • Capabilities include testing for COVID-19 antibodies
  • Data generated will aid clinical research and the development of new therapeutics
  • Bloom Diagnostics closed US$11.7 million Series B funding

ZURICH, VIENNA, NEW YORK: Swiss medtech company Bloom Diagnostics, today unveiled its new Bloom System enabling users to conduct smart COVID-19  antibody testing with real-time results. The Bloom System aims to eliminate long waiting times for tests and relieve pressure on healthcare systems already under strain due to large testing volumes linked to COVID-19. Bloom Diagnostics is an innovative medtech company that is developing a smart diagnostic system for a wide range of medical conditions.

The Bloom System aims to impact the healthcare market by making smart testing accessible to everyone. Pin-prick blood samples are captured in the Bloom Test strip and then deployed into the Bloom Lab. Following that, cloud-based algorithms aggregate test results with other measurable indicators of illness alongside medical history, lifestyle and individual symptoms giving immediate and fully encrypted feedback through a personalized report on the Bloom App. The entire smart testing process takes around ten minutes.

The digital connectivity era has meant there is a growing need for healthcare professionals to be in direct contact with their users and patients. The Bloom System is designed for consumers to easily collect, track and share health biomarkers with medical practitioners. Reacting to the onset of the Coronavirus pandemic, Bloom Diagnostics has developed a fully integrated COVID-19 serological test for professional use into the Bloom System, validated by Professor Adriano Aguzzi, director of the Institute of Neuropathology at the University Hospital Zurich. The test can help authorities understand the rate of spread and immunity development in a certain region and may be valuable to track the effectiveness of a vaccine. The data also allows for insights such as the rate of infection among different age groups and genders, geographical locations and connections to other diseases.

Bloom Diagnostics is preparing to launch its COVID-19 antibody test for professionals to prove the ease of use and demonstrate the value of the real time feedback to lay users in a controlled professional environment first. The Bloom COVID-19 Test will not only help  relieve healthcare systems around the globe, but also support them with valuable data of the pandemic and immunity after an infection with SARS-CoV-2.

Bloom Diagnostics was founded in 2018 by Angelica Kohlmann and Thomas Kupper. The company recently closed a US$11.7 million Series B funding round which will be used for additional R&D and to drive expansion throughout Europe and the US. Among their early investors are Speedinvest from Austria and Canadian Walter Group.

The ISO-certified company is in the process of securing CE marking in Europe in Q3 2020. Bloom Diagnostics aims to rapidly add to its range of capabilities to accelerate the pace of clinical discoveries and, ultimately, the development of new therapies.

“Bloom was founded to change the way healthcare works, reducing costs and making it more accessible to all, globally,” said Angelica Kohlmann, MD PhD, Chairperson at Bloom Diagnostics, who started her career in cancer research. “Additionally, Bloom learns from anonymous and encrypted data every day, leading to better products. This is especially important in the case of COVID-19 – a new condition with many unknowns. Bloom can contribute significantly to the better understanding of the disease and help governments and authorities to react faster. New insights may eventually lead to better therapies.”

Thomas Kupper, Co-founder and Chief Product Officer at Bloom, said: “There is a need for a tertiary layer of diagnostic devices between individuals and the traditional healthcare system. This layer has seen its inception with products like the first LFA-based pregnancy tests in the 1970s. We think it’s overdue that this layer develops into something much more elaborate, helping individuals gain insights into their health in a wide range of situations. Combining those insights, globally, anonymized and in real time, will generate improvements that benefit the public. We don’t see ourselves as a replacement for many players of the traditional healthcare industry, but as a direly needed ally to support an overburdened system.”

Thomas Pfisterer from WILD Group, which led the Series B round, added “The time is right to invest in such an exciting and disruptive company. The high-caliber, international team has developed a diagnostics/healthcare solution based on biotechnology, electronics and data science that is unique and will change the world of healthcare and prevention.”

For more on Bloom Diagnostics please see www.bloomdiagnostics.com/

 

Notes to Editor:

About Bloom Diagnostics
Bloom Diagnostics is an innovative medtech company whose hardware and software can identify a range of medical conditions, using a combination of advanced biotechnology, cloud computing and scientific research. Bloom Diagnostics’ sophisticated system allows consumers to take control of their own health. Through it’s next-generation technology and personalized data insights, Bloom Diagnostics applies machine learning to improve results and analyze data that may eventually help develop new therapeutics.

Angelica Kohlmann
Angelica Kohlmann serves as Chairperson of the non-executive Board of the Company. She holds a MD and doctorate in medicine from Hamburg University (GER). She has been Chairperson of the Advisory Board Peter Drucker Society Europe / Global Peter Drucker Forum, Vienna (since 2009) and is a non-executive Board member of private and public companies including Teralytics AG (since 2014) and Lonza Group (since 2018). She is also a serial investor in successful companies, with multiple exits, as the latest of CTRL-labs, which was sold to Facebook in 2019.

 

For interview requests or media enquiries, please contact:

Anna-Kate Bennington
Senior Account Executive 
ClearStory International
M: +353 083 375 3798 
O: +353 (0)196 100 48